Supernus Pharmaceuticals Price to Sales Ratio 2011-2024 | SUPN

Historical PS ratio values for Supernus Pharmaceuticals (SUPN) over the last 10 years. The current P/S ratio for Supernus Pharmaceuticals as of November 20, 2024 is . For more information on how our historical price data is adjusted see the Stock Price Adjustment Guide.
Supernus Pharmaceuticals P/S Ratio Historical Data
Date Stock Price TTM Sales per Share Price to Sales Ratio
2024-11-19 35.53 3.04
2024-09-30 31.18 $11.70 2.67
2024-06-30 26.75 $11.38 2.35
2024-03-31 34.11 $10.85 3.14
2023-12-31 28.94 $10.73 2.70
2023-09-30 27.57 $10.48 2.63
2023-06-30 30.06 $10.88 2.76
2023-03-31 36.23 $11.17 3.24
2022-12-31 35.67 $11.19 3.19
2022-09-30 33.85 $11.40 2.97
2022-06-30 28.92 $10.91 2.65
2022-03-31 32.32 $10.72 3.01
2021-12-31 29.16 $10.66 2.74
2021-09-30 26.67 $10.40 2.56
2021-06-30 30.79 $10.56 2.92
2021-03-31 26.18 $10.34 2.53
2020-12-31 25.16 $9.69 2.60
2020-09-30 20.84 $8.89 2.35
2020-06-30 23.75 $7.90 3.01
2020-03-31 17.99 $7.48 2.41
2019-12-31 23.72 $7.29 3.25
2019-09-30 27.48 $7.57 3.63
2019-06-30 33.09 $7.57 4.37
2019-03-31 35.04 $7.46 4.70
2018-12-31 33.22 $7.56 4.39
2018-09-30 50.35 $7.08 7.12
2018-06-30 59.85 $6.68 8.97
2018-03-31 45.80 $6.26 7.31
2017-12-31 39.85 $5.67 7.02
2017-09-30 40.00 $5.22 7.66
2017-06-30 43.10 $4.82 8.95
2017-03-31 31.30 $4.39 7.13
2016-12-31 25.25 $4.16 6.07
2016-09-30 24.73 $3.81 6.49
2016-06-30 20.37 $3.48 5.86
2016-03-31 15.25 $3.16 4.82
2015-12-31 13.44 $2.94 4.57
2015-09-30 14.03 $2.82 4.97
2015-06-30 16.98 $2.59 6.55
2015-03-31 12.09 $2.61 4.64
2014-12-31 8.30 $2.19 3.79
2014-09-30 8.69 $1.77 4.90
2014-06-30 10.95 $1.29 8.51
2014-03-31 8.94 $0.59 15.03
2013-12-31 7.54 $0.38 19.90
2013-09-30 7.33 $0.12 62.66
2013-06-30 6.43 $0.08 80.30
2013-03-31 5.62 $0.08 73.57
Sector Industry Market Cap Revenue
Medical Medical - Generic Drugs $1.962B $0.608B
Supernus Pharmaceuticals Inc. is a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases. It is developing several product candidates in neurology and psychiatry to address opportunities in epilepsy and attention deficit hyperactivity disorder. Supernus Pharmaceuticals Inc. is based in Rockville, Maryland.
Stock Name Country Market Cap PE Ratio
Teva Pharmaceutical Industries (TEVA) Israel $19.044B 6.25
Dr Reddy's Laboratories (RDY) India $11.978B 22.92
BridgeBio Pharma (BBIO) United States $4.260B 0.00
Bausch Health Cos (BHC) Canada $3.012B 2.18
Amphastar Pharmaceuticals (AMPH) United States $2.097B 12.61
Taysha Gene Therapies (TSHA) United States $0.434B 30.29
Personalis (PSNL) United States $0.261B 0.00
Assembly Biosciences (ASMB) United States $0.098B 0.00
Sol-Gel Technologies (SLGL) Israel $0.012B 0.00
Evoke Pharma (EVOK) United States $0.007B 0.00
Teligent (TLGT) United States $0.000B 0.00